During the second wave of COVID-19, Dexamethasone and Methylprednisolone were also utilized in treating COVID patients; however, maintaining consistent supply posed a significant challenge.

22% with melphalan and prednisone, 15% with high-dose melphalan, 11% with dexamethasone and lenalidomide, 8% with melphalan, prednisone and bortezomib, and 4% with intermediate-dose melphalan.